Molipaxin
In brief
- In our pharmacy, you can buy Molipaxin without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging.
- Molipaxin (trazodone) is used to treat major depressive disorder and is commonly used off‑label for insomnia; it is a serotonin antagonist and reuptake inhibitor (SARI) — it blocks 5‑HT2A receptors and inhibits serotonin reuptake, with additional antihistaminic and alpha‑1 adrenergic blocking effects that contribute to sedation.
- Usual adult dosages: for depression start around 150 mg/day in divided doses increased to 300 mg/day if needed (up to 600 mg/day in hospital); for insomnia lower doses of 25–100 mg at bedtime are commonly used, usually not exceeding 150 mg for sleep.
- Administered orally as tablets, capsules or oral solution; take with or without food as directed by the product label or clinician.
- For sleep, effects are often felt within 30–60 minutes; antidepressant benefits may begin in 1–2 weeks with full effect typically by 4–6 weeks.
- The sedative effect from a single dose commonly lasts about 6–12 hours; antidepressant benefit requires continued treatment over weeks and maintenance use to prevent relapse.
- Do not combine Molipaxin with alcohol — alcohol increases drowsiness, dizziness and the risk of respiratory depression and other adverse effects.
- The most common side effect is drowsiness/sedation (other frequent effects include dry mouth, dizziness, headache, blurred vision, constipation and orthostatic hypotension).
- Would you like to try Molipaxin without a prescription?
Basic Molipaxin information
- INN (international nonproprietary name): Trazodone
- Brand names available in the United Kingdom: Molipaxin; generic trazodone
- ATC code: N06AX05
- Forms and strengths: capsules 50 mg, 100 mg; tablets 150 mg; oral solution
- Manufacturers: Angelini Pharma (originator); multiple generic manufacturers including Teva, Sandoz, Mylan
- OTC / Rx classification: Prescription-only (never OTC)
Legal status and availability in the UK
In our online pharmacy, Molipaxin is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Clinical effectiveness in the UK
How well does Molipaxin (trazodone) work in UK practice?
Trazodone can be useful for major depressive disorder when insomnia coexists.
Antidepressant effects tend to start within 1–2 weeks, with fuller benefit by 4–6 weeks.
UK prescribers particularly value trazodone’s sedating properties for patients whose sleep disturbance is a prominent symptom, but responses vary compared with SSRIs.
Response to Molipaxin is usually monitored with PHQ‑9 and GAD‑7 score shifts, sleep diary changes, functional outcomes such as work and ADLs, and adverse event rates including falls and orthostatic hypotension.
| Outcome measure | When to review | Clinical decision point |
|---|---|---|
| PHQ‑9 | Baseline, 4–6 weeks, 3 months | Response or switch if inadequate by 6 weeks |
| Sleep diary / sleep scores | Baseline, 2–4 weeks | Continue low‑dose strategy if sleep improves |
| Falls / orthostatic events | 2–6 weeks after start or dose change | Dose reduction or alternative if risk increases |
Expected timelines: onset 1–2 weeks; full effect typically by 4–6 weeks.
Treatment continuation following symptom remission commonly lasts several months.
Indications and expanded uses
Which patients are likely to be prescribed Molipaxin?
In the UK, trazodone is licensed for depressive illness (with or without anxiety) and for anxiety.
In UK clinical practice, off‑label uses of trazodone include low‑dose hypnotic therapy for insomnia and adjunctive treatment for SSRI‑resistant depression.
Typical Molipaxin use cases include primary depression including treatment‑resistant cases, insomnia where depression is present, and as part of combination regimens with other antidepressants or adjunctive agents.
- Licensed uses: depressive illness (with or without anxiety); anxiety.
- Off‑label uses: Low‑dose hypnotic for insomnia; adjunctive therapy for SSRI non‑response.
Definitions: licensed means approved for the indication by a regulator; off‑label means clinically used outside the licence and requires documented rationale; unlicensed means the product has no marketing authorisation in that setting.
Ethical and regulatory note: off‑label prescribing within the NHS requires documented rationale, informed consent and safety monitoring.
Prescribers should check MHRA guidance and local formularies.
Composition and brand landscape
Molipaxin is a UK brand name of trazodone.
The INN is trazodone, and the medicine is supplied both as Molipaxin and as generic trazodone, as 50 mg and 100 mg capsules, 150 mg tablets and an oral solution.
Trazodone was originally developed by Angelini, and generic versions are made by companies such as Teva, Sandoz and Mylan.
Its ATC classification is N06AX05.
Packaging and excipient differences matter for allergy checks and supply continuity.
Contraindications and special precautions
Who should not take Molipaxin?
Absolute contraindications to Molipaxin include known hypersensitivity and concurrent use with MAO inhibitors.
The acute recovery phase following myocardial infarction is also a contraindication.
Relative cautions include cardiac disease such as arrhythmias or heart block, hepatic or renal impairment, a history of seizures, and risk of angle‑closure glaucoma.
Older adults need lower starting doses because sedation and orthostatic hypotension are more likely.
Pregnancy and breastfeeding require specialist advice and the drug should be used only if the potential benefit justifies the potential risk.
- Absolute contraindications: Hypersensitivity to trazodone; concurrent MAOI use; acute post‑MI recovery.
- Relative contraindications: Cardiac disease; hepatic/renal impairment; seizure history; angle‑closure glaucoma risk; current suicidality requires close monitoring.
Practical patient advice: avoid driving or operating machinery until tolerance is established, avoid heavy alcohol intake and report dizziness or fainting.
Report suspected adverse reactions via the Yellow Card scheme as part of MHRA vigilance.
Dosage guidelines
How is Molipaxin dosed?
For depression, the usual adult starting dose is 150 mg/day in divided doses or as a single bedtime dose, increased to 300 mg/day if needed; hospital patients may receive up to 600 mg/day.
For low‑dose bedtime use targeting insomnia, common ranges are 25–100 mg, typically not exceeding 150 mg.
| Indication | Typical starting dose | Usual maximum |
|---|---|---|
| Depression | 150 mg/day | 300 mg/day; up to 600 mg in hospital |
| Insomnia (low‑dose, off‑label) | 25–100 mg at bedtime | Generally ≤150 mg |
Formulations include 50 mg and 100 mg capsules, 150 mg tablets and an oral solution.
Do not use in paediatric patients as safety and efficacy are unestablished.
Start lower and titrate more slowly in elderly patients and those with hepatic or renal impairment.
Counselling point: reduce dose gradually when stopping to minimise withdrawal symptoms and schedule an early review at 2–6 weeks after initiation.
Interactions overview
What medicines should not be mixed with Molipaxin?
Concurrent MAO inhibitors are contraindicated and combining with other serotonergic drugs raises the risk of serotonin syndrome.
CYP3A4 inhibitors can raise plasma levels of trazodone and worsen adverse effects, so dose adjustments or alternatives should be considered.
Combining with other central nervous system depressants such as benzodiazepines or opioids increases sedation and respiratory risk.
Antihypertensives may have additive effects causing orthostatic hypotension, and QT‑prolonging agents should be used with caution in patients with cardiac disease.
Alcohol increases sedation and should be avoided while taking Molipaxin.
Pharmacy practice point: check for interactions before issuing Molipaxin prescriptions.
Comparable medicines and preferences
Which drugs will clinicians consider instead of Molipaxin?
Key comparators include mirtazapine, amitriptyline and SSRIs such as sertraline and paroxetine.
Clinicians weigh sedative effect, sexual side‑effect risk, anticholinergic burden and withdrawal potential when choosing between options.
| Drug | Indication fit | Sedative effect | Notable risks |
|---|---|---|---|
| Mirtazapine | Depression with insomnia | High | Weight gain; less sexual dysfunction |
| Amitriptyline | Depression; neuropathic dosing | High | Anticholinergic burden; cardiac risk |
| Sertraline / Paroxetine | Depression ± anxiety | Low to moderate | SSRI side effects; paroxetine notable for withdrawal |
In NHS primary care, sedating agents such as mirtazapine or trazodone‑class drugs are often chosen when insomnia is prominent or in frail elderly patients at low doses.
Shared decision aids should present pros and cons along with expected benefit timelines and monitoring needs.
Frequently asked questions
Can I get Molipaxin on the NHS?
Trazodone can be prescribed on the NHS; you may receive generic trazodone rather than the Molipaxin brand.
Is it safe to drive?
Avoid driving until you know how Molipaxin affects you because sedation and orthostatic hypotension are common.
What if I miss a dose?
Take the missed dose as soon as you remember unless the next dose is due soon; do not double up to make up for a missed dose.
How long before it works?
Early effects can appear within 1–2 weeks and a fuller antidepressant benefit is often seen by 4–6 weeks.
Can I drink alcohol?
Alcohol amplifies sedation and is best avoided while taking Molipaxin.
Guidelines for proper use
What should pharmacists check before dispensing Molipaxin?
Confirm prescription validity, check for MAOI use and review cardiac history before dispensing.
Counsel patients on sedation and orthostatic precautions and document consent for any off‑label use.
- Verify indication and dose.
- Flag elderly patients and those with hepatic or renal impairment for dose review.
- Advise on avoiding driving and alcohol until tolerance is established.
- Schedule follow‑up in 2–6 weeks and use PHQ‑9 or sleep diaries to monitor response.
- Report adverse events via the Yellow Card scheme.
For discharge or care‑home settings, provide clear monitoring instructions and communicate with primary care.
Patient education materials should be brief, culturally sensitive and available in common community languages.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | Greater London | 9–21 days |
| Birmingham | West Midlands | 9–21 days |
| Manchester | Greater Manchester | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | West Yorkshire | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Liverpool | Merseyside | 9–21 days |
| Bristol | South West | 9–21 days |
| Sheffield | South Yorkshire | 9–21 days |
| Newcastle | Tyne and Wear | 9–21 days |
| Nottingham | Nottinghamshire | 9–21 days |
| Leicester | Leicestershire | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Plymouth | Devon | 9–21 days |
